Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.465 +0.205 (+2.21%)

Streaming Delayed Price Updated: 11:55 AM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,202,742
Open	9.590
Bid (Size)	9.460 (1,100)
Ask (Size)	9.470 (400)
Prev. Close	9.260
Today's Range	9.315 - 9.770
52wk Range	7.210 - 25.67
Shares Outstanding	196,357,149
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.

April 01, 2026

From Kirby McInerney LLP

Via Business Wire

Performance

YTD	-47.1%	-47.1%
1 Month	-40.1%	-40.1%
3 Month	-48.4%	-48.4%
6 Month	-32.3%	-32.3%
1 Year	-48.6%	-48.6%

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

March 31, 2026

From Kirby McInerney LLP

Via GlobeNewswire

ADMA Biologics Inc (NASDAQ:ADMA) Reports Record 2025 Results Driven by ASCENIV, Provides 2026 Outlook ↗

February 25, 2026

Via Chartmill

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

March 27, 2026

From Kirby McInerney LLP

Via Business Wire

The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants

March 27, 2026

Via MarketMinute

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

March 27, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

What's going on in today's pre-market session ↗

March 27, 2026

Via Chartmill

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

March 27, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law

March 26, 2026

From Bleichmar Fonti & Auld LLP

Via Business Wire

Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

March 26, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Why Are Shares Of ADMA Biologics Falling Today? ↗

March 26, 2026

Via Benzinga

ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 26, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

March 25, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

ADMA Biologics Addresses Misleading Short-Seller Report

March 25, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

March 02, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗

February 28, 2026

Via The Motley Fool

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 18, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗

February 14, 2026

Via The Motley Fool

Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗

February 14, 2026

Via The Motley Fool

Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗

February 14, 2026

Via The Motley Fool

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

January 12, 2026

From ADMA Biologics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is ADMA Biologics Inc - Common Stock publicly traded?

Yes, ADMA Biologics Inc - Common Stock is publicly traded.

What exchange does ADMA Biologics Inc - Common Stock trade on?

ADMA Biologics Inc - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ADMA Biologics Inc - Common Stock?

The ticker symbol for ADMA Biologics Inc - Common Stock is ADMA on the Nasdaq Stock Market

What is the current price of ADMA Biologics Inc - Common Stock?

The current price of ADMA Biologics Inc - Common Stock is 9.465

When was ADMA Biologics Inc - Common Stock last traded?

The last trade of ADMA Biologics Inc - Common Stock was at 04/08/26 11:55 AM ET

What is the market capitalization of ADMA Biologics Inc - Common Stock?

The market capitalization of ADMA Biologics Inc - Common Stock is 1.86B

How many shares of ADMA Biologics Inc - Common Stock are outstanding?

ADMA Biologics Inc - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.